Heartflow, Inc. (HTFL) said its Chief Medical Officer, Campbell Rogers, sold 64,533 shares of common stock on March 19, 2026. The shares fetched approximately $1.66 million in aggregate, at a weighted average sale price of $25.6928. Individual sale prices reported ranged from $25.00 to $28.00 per share.
The stock sale coincided with a sharp uptick in Heartflow's share price - the company has seen its stock climb 28% over the previous week. At the time of the filing referenced in this report, the shares were trading at $26.80 and the company carried a market capitalization of $2.23 billion.
Information disclosed in a Form 4 filed with the Securities and Exchange Commission shows Rogers also exercised two sets of options to acquire common stock on the same day. He exercised options to purchase 19,402 shares and 47,615 shares of Heartflow common stock at an exercise price of $2.22 per share, resulting in cash outlays recorded as $43,072 and $105,705 for the respective option blocks.
Those option exercises and the subsequent sale of shares were carried out under a pre-arranged Rule 10b5-1 trading plan that Rogers adopted on September 12, 2025. Following these transactions Rogers directly owns 78,518 shares of Heartflow common stock. He also retains indirect holdings through various trusts, as noted in the filing.
On the corporate performance front, Heartflow recently released its fourth-quarter results, which outpaced expectations on several metrics. The company reported revenue of $49.1 million, above the consensus estimate of $46.6 million, representing a 40% increase year-over-year. Reported earnings per share were -$0.12, better than the forecasted -$0.15.
Analyst response to those results has been favorable. Piper Sandler reiterated an Overweight rating and set a $38.00 price target. Canaccord increased its price target to $43 while maintaining a Buy rating, citing the strong quarterly performance and initial 2026 guidance. These analyst notes reflect positive sentiment following the reported quarter.
Separately, InvestingPro assigns Heartflow a financial health score of "GOOD," noting that liquid assets exceed short-term obligations and that the company has a strong current ratio of 5.2. The InvestingPro assessment also indicates that the stock appears overvalued relative to its Fair Value, per their analysis.
The filings and company disclosures present a combination of insider liquidity actions, option exercises under an established trading plan, recent operational outperformance, and mixed valuation signals from data providers and analysts.